# Authorizing Official Briefing

## Decision Summary

**Recommendation: AUTHORIZE WITH CONDITIONS**

The clinical BCI decision-support system presents material AI-specific risk but can proceed under controlled authorization conditions if the identified high-residual risks, human-oversight requirements, model-change controls, provenance gaps, and explainability limitations remain subject to documented treatment and continuing monitoring.

## Overall Risk Posture

- Total registered AI risks: 8
- Average inherent risk score: 18.25/25
- Maximum inherent risk score: 20/25
- Unresolved or actively mitigating risks: 8
- Risks scoring 20–25: 5
- Risks scoring 15–19: 3
- High/Critical residual risks after mapped controls: 4

## Top 3 Unresolved Risks

### 1. AI-RISK-002 — Representational harm

- Initial score: 20/25
- Residual risk: High
- Lifecycle stage: Training
- Business impact: Underrepresented cohorts could receive unequal clinical decision-support quality.

### 2. AI-RISK-003 — Quality-of-service harm

- Initial score: 20/25
- Residual risk: High
- Lifecycle stage: Deployment
- Business impact: Clinicians may lack sufficient reasoning evidence to safely trust or challenge model outputs.

### 3. AI-RISK-007 — Allocative harm

- Initial score: 20/25
- Residual risk: High
- Lifecycle stage: Operation
- Business impact: Automation bias could cause physicians to over-rely on model outputs.

## Black-Box / Explainability Limitation

The neural-network classifier remains a black-box model for which conventional SP 800-53 controls do not provide an adequate direct mapping for prediction-level explainability. Integrity, monitoring, risk assessment, privacy, training, and supply-chain controls can reduce surrounding system risk, but they do not make the internal decision logic inherently interpretable.

Residual explainability risk should therefore be accepted only with AI-specific compensating safeguards: human-in-the-loop authority, feature-attribution evidence where feasible, uncertainty communication, clinician usability validation, documented limitations, and explicit residual-risk approval.

## Authorization Conditions

1. No autonomous diagnosis or treatment decision is permitted.
2. Qualified clinicians retain final decision authority.
3. Material retraining requires independent re-validation before deployment.
4. Cohort-level performance and bias metrics must remain within approved thresholds.
5. Production drift monitoring must remain active.
6. Third-party model provenance gaps must be tracked and escalated.
7. Sensitive neural-data privacy controls must be continuously enforced.
8. High-residual risks require assigned owners and documented treatment milestones.
9. Black-box explainability limitations require explicit residual-risk acceptance.
10. Significant safety, privacy, model, data, or supplier changes trigger authorization review.

## Authorization Rationale

Denying authorization is not currently recommended because the system is designed as clinical decision support rather than autonomous clinical decision-making, and meaningful compensating controls are available for most identified risks. Unconditional authorization is also not appropriate because several risks remain high after conventional control mapping, particularly explainability, automation bias, cohort bias, and supplier provenance. Conditional authorization provides the most defensible posture while requiring continued evidence, monitoring, and human oversight.
